Oxford scientists have hailed a cheap steroid as a 'major breakthrough' in the fight against Covid-19 after it was found to reduce deaths by up to a third among patients suffering the worst effects of the virus.

The mortality rate of those who end up on a ventilator is above 40 per cent, but this was reduced by a third among people prescribed dexamethasone.

More than 11,500 patients from 175 NHS hospitals have been enrolled on the Recovery trial, co-ordinated by Oxford University, since it was set up in March to test a range of potential coronavirus treatments.

READ MORE: Oxford University bursar who thought he would die in the JR with Covid-19 on joining Recovery drug trial

In the dexamethasone study, 2,104 patients received 6mg of dexamethasone once a day by mouth or intravenous injection for 10 days.

Their outcomes were compared with a control group of 4,321 patients.

Over a 28-day period, the mortality rate among patients requiring ventilation was 41 per cent, and for those needing oxygen it was 25 per cent.

Among those not requiring respiratory intervention the figure was 13 per cent.

The study revealed the steroid reduced deaths by a third in ventilated patients and a fifth in people needing oxygen.

ALSO READ: How coronavirus could change GP surgeries forever

There was no change in deaths among patients who did not require respiratory support.

Peter Horby, professor of emerging infectious diseases at Oxford University’s Nuffield Department of Medicine, and one of the chief investigators for the trial, described it as 'an extremely welcome result'.

He said: “This is the only drug that has so far shown to reduce mortality, and it reduces it significantly. It is a major breakthrough, I think.

“Dexamethasone is inexpensive, on the shelf, and can be used immediately to save lives worldwide.”

Martin Landray, professor of medicine and epidemiology at the Nuffield Department of Population Health, and another chief investigator, said: “Covid-19 is a global disease – it is fantastic that the first treatment demonstrated to reduce mortality is one that is instantly available and affordable worldwide.

“It’s been around for probably 60 years.

“It costs in the order of £5… for a complete course of treatment in the NHS, and substantially less – probably less than one dollar – in other parts of the world, for example in India.”

The research team is working to publish the full results of the study as quickly as possible.

ALSO READ: Calls for Bicester Village to shut over 'squashed' crowds

Commenting on the results of the Recorvery trial, NHS chief executive Simon Stevens said: "NHS hospitals, researchers and clinicians have worked together at breakneck speed to test new treatments for Covid-19, and it is amazing to see work that would normally take years bear fruit in just a matter of months.

"This research agility is not only important for coronavirus patients, but augurs well for the streamlined innovation that the NHS and the UK life sciences now must pioneer."

Professor Stephen Powis, NHS medical director added: “This is a huge breakthrough in our search for new ways to successfully treat patients with covid, both in the UK and across the world. 

"It is thanks to NHS staff and patients who participated in the trial that from now, we are able to use this drug to dramatically improve Covid-19 survival for people in hospital who require oxygen or ventilation.”